| Negative Results: Relaxin ® Clinical Trials for Scleroderma |
| Phase III Relaxin Trial Did Not Reach Primary Endpoint. Relaxin is of no value for the treatment of scleroderma. |
| "Scleroderma has again proven to be an extremely difficult disease for which to develop a therapeutic treatment." Connetics 10-8-00. |
| Related Links |
| Scleroderma Research Registries. ISN. |
| Scleroderma Treatments & Clinical Trials. ISN. |
| Ineffective or Unproven Treatments for Scleroderma. ISN. |
|
||||||||||||
| Go to Scleroderma Clinical Trials: Positive Results | ||||||||||||
|
||||||||||||